---
figid: PMC9163533__bmjopen-2021-056147f01
pmcid: PMC9163533
image_filename: bmjopen-2021-056147f01.jpg
figure_link: /pmc/articles/PMC9163533/figure/F1/
number: Figure 1
figure_title: ''
caption: Overall survival in MRC-IX and NCRI-XI TE pathway (A). Overall survival in
  MRC-IX and NCRI-XI TNE pathway (B). MRC-IX, Medical Research Council Myeloma IX
  trial (ISRCTN49407852); NCRI-XI, National Cancer Research Institute Myeloma XI Trial
  (ISRCTN68454111); TE, transplant eligible; TNE, transplant non-eligible.
article_title: 'Frailty-adjusted therapy in Transplant Non-Eligible patients with
  newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol
  for a randomised phase III trial.'
citation: Amy Beth Coulson, et al. BMJ Open. 2022;12(6):e056147.
year: '2022'

doi: 10.1136/bmjopen-2021-056147
journal_title: BMJ Open
journal_nlm_ta: BMJ Open
publisher_name: BMJ Publishing Group

keywords:
- Myeloma
- CHEMOTHERAPY
- Clinical trials

---
